Definium Therapeutics (NASDAQ:DFTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Definium Therapeutics (NASDAQ:DFTX) from a sell rating to a hold rating in a research note published on Sunday.

Several other equities analysts have also issued reports on the company. Piper Sandler restated an “overweight” rating and set a $73.00 price target (up from $48.00) on shares of Definium Therapeutics in a research note on Friday. Needham & Company LLC lifted their price objective on Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd. Stifel Nicolaus boosted their price objective on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Finally, Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Definium Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $52.36.

Definium Therapeutics Trading Down 1.6%

Shares of DFTX stock opened at $41.96 on Friday. The firm has a market capitalization of $4.18 billion, a P/E ratio of -16.85 and a beta of 2.20. Definium Therapeutics has a 1 year low of $7.96 and a 1 year high of $49.20. The firm’s fifty day simple moving average is $34.53 and its 200 day simple moving average is $24.30. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, sell-side analysts predict that Definium Therapeutics will post -2.27 EPS for the current year.

Insiders Place Their Bets

In other news, insider Mark Sullivan sold 13,008 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the transaction, the insider directly owned 320,571 shares of the company’s stock, valued at $14,435,312.13. The trade was a 3.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert Barrow sold 29,208 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 48,096 shares of company stock valued at $2,165,763 over the last quarter. 2.40% of the stock is owned by insiders.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares during the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Definium Therapeutics in the fourth quarter worth about $117,000. Caxton Associates LLP acquired a new position in shares of Definium Therapeutics during the third quarter worth approximately $126,000. Finally, Mercer Global Advisors Inc. ADV lifted its position in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after purchasing an additional 2,079 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.